Key result
Gene therapy utilizing viral and non-viral vectors to deliver anti-inflammatory genes shows potential in animal models for treating arthritis, though clinical application is limited by safety concerns.
Gene therapy offers a promising approach for rheumatoid arthritis by potentially providing long-term, localized delivery of therapeutic proteins, overcoming the limitations of frequent systemic administration of current biologic DMARDs.
Gene transfer may enable sustained arthritis therapy; leaves open the need for clinical translation studies.
Arthritis is among the leading causes of disability in the developed world. There remains no cure for this disease and the current treatments are only modestly effective at slowing the disease's progression and providing symptomatic relief. The clinical effectiveness of current treatment regimens has been limited by short half-lives of the drugs and the requirement for repeated systemic administration. Utilizing gene transfer approaches for the treatment of arthritis may overcome some of the obstacles associated with current treatment strategies. The present review examines recent developments in gene therapy for arthritis. Delivery strategies, gene transfer vectors, candidate genes, and safety are also discussed.
No takes yet. Share an insight, caveat, or question.
Traister et al. (2008) conducted a review in Rheumatoid arthritis. Gene therapy was evaluated. Gene therapy utilizing viral and non-viral vectors to deliver anti-inflammatory genes shows potential in animal models for treating arthritis, though clinical application is limited by safety concerns.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: